CLYM Projected Dividend Yield
Climb Bio Inc ( NASDAQ : CLYM )Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. Co. is focused on developing therapeutics for patients with immune-mediated diseases. Co.'s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial. 21 YEAR PERFORMANCE RESULTS |
CLYM Dividend History Detail CLYM Dividend News CLYM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |